DS
PVLA

DRW Securities’s Palvella Therapeutics PVLA Stock Holding History

DRW Securities’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,265
Closed -$476K – 176
2019
Q2 		$476K Buy
1,265
+15
+1% +$4.47K 0.03% 74
2019
Q1 		$335K Buy
+1,250
New +$297K 0.01% 61
2018
Q4 		– Sell
-1,000
Closed -$448K – 92
2018
Q3 		$448K Buy
1,000
+437
+78% +$190K 0.02% 30
2018
Q2 		$228K Buy
563
+188
+50% +$89.5K 0.01% 65
2018
Q1 		$205K Buy
375
+87
+30% +$53.9K 0.01% 117
2017
Q4 		$174K Buy
+288
New +$134K 0.02% 423

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

DRW Securities's PVLA Position: Q3 2019 in Review

DRW Securities sold out of Palvella Therapeutics (PVLA) in Q3 2019, closing a stake of 1,265 shares — an estimated $476K sold.

DRW Securities first reported a position in PVLA in Q4 2017 and held it in 6 quarters. The position peaked at $476K in Q2 2019. 98 funds tracked by Wall St. Rank hold PVLA as of Q3 2019.

  • DRW Securities reported no remaining Palvella Therapeutics position as of Q3 2019 after selling out during the quarter.
  • DRW Securities sold 1,265 Palvella Therapeutics shares in Q3 2019, an estimated $476K.
  • DRW Securities first reported a position in Palvella Therapeutics in Q4 2017 and held it in 6 quarters.
  • DRW Securities's Palvella Therapeutics position peaked at $476K in Q2 2019.
  • 98 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2019.

Based on DRW Securities's 13F filing for Q3 2019, filed 14 Nov 2019.